Drug intelligence / Profile preview

walnut peptide

Development stage
Preclinical
Lead developer
Beijing SEMNL Biotechnology
Modality
Small Molecules, Peptides
Administration
Oral
01

Overview

Walnut peptide is a mixture of small molecular peptides derived from the enzymatic hydrolysis of walnut (Juglans regia L.) proteins. These peptides typically have molecular weights less than 6000 Da and are often enriched for fractions below 1000 Da[1][2][3]. Walnut peptides exhibit a range of biological activities including antioxidant, anti-inflammatory, antihypertensive (ACE inhibitory), neuroprotective (memory-enhancing), anti-cancer, anti-fatigue effects, and modulation of gut microbiota[1][2][3][4][5]. Mechanistically, specific sequences such as YVPFPLP (YP-7) have been shown to activate peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) and inhibit the extracellular regulated protein kinase pathway in neuronal cells[4]. Other studies indicate that certain peptides modulate TLR4-MAPK signaling to reduce inflammation in colitis models[5], while ACE inhibition is achieved through mixed-type binding at both active and inactive sites on the enzyme[1]. Walnut peptides are more easily absorbed than intact proteins or free amino acids due to their oligopeptide structure. They are used primarily as dietary supplements or functional food ingredients for health promotion.

Other names
walnut oligopeptideWOPWPJuglans regia L. peptidewalnut protein hydrolysate
02

Targets

TLR4 (Toll-like receptor 4)ACE (Angiotensin Converting Enzyme)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on walnut peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on walnut peptide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call